Trademark: 88981754
Word
SYNGENE
Status
Registered
Status Code
700
Status Date
Tuesday, June 29, 2021
Serial Number
88981754
Registration Number
6405032
Registration Date
Tuesday, June 29, 2021
Mark Type
5000
Filing Date
Thursday, August 16, 2018
Published for Opposition
Tuesday, January 14, 2020

Trademark Owner History
SYNGENE INTERNATIONAL LIMITED - Original Registrant

Classifications
35 Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications
42 Scientific research and custom synthesis; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing; laboratory testing services for research and development purposes; testing of pharmaceuticals; chemical engineering; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of animal; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; conducting clinical trials; conducting clinical trials for scientific research for others; conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; preparation of reports relating to scientific and technical research; analysis in the field of molecular biology; contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific and medical laboratory services; services of a chemical and/or biological laboratory; laboratory research services relating to pharmaceuticals; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, cheminformatics, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, and solid state characterization; toxicokinetic analysis and toxicology services; scientific and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, genes, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbials, monomers, nanoparticles, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications, and none of the aforesaid services in the field of agriculture, horticulture and forestry
The mark consists of the word "Syngene" in stylized font.
Color is not claimed as a feature of the mark.

Trademark Events
Jun 2, 2023
Teas Withdrawal Of Attorney Received-Firm Retains
Jun 2, 2023
Teas Change Of Correspondence Received
Jun 2, 2023
Teas Change Of Domestic Representatives Address
Jun 2, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 2, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 2, 2023
Teas Change Of Owner Address Received
Jun 29, 2021
Registered-Principal Register
May 28, 2021
Notice Of Acceptance Of Statement Of Use E-Mailed
May 27, 2021
Allowed Principal Register - Sou Accepted
May 26, 2021
Statement Of Use Processing Complete
May 6, 2021
Use Amendment Filed
May 26, 2021
Divisional Processing Complete
May 6, 2021
Divisional Request Received
May 26, 2021
Case Assigned To Intent To Use Paralegal
May 6, 2021
Teas Request To Divide Received
May 6, 2021
Teas Statement Of Use Received
Mar 3, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 1, 2021
Sou Extension 1 Granted
Mar 1, 2021
Sou Extension 1 Filed
Mar 1, 2021
Teas Extension Received
Sep 1, 2020
Noa E-Mailed - Sou Required From Applicant
Jul 23, 2020
Extension Of Time To Oppose Process - Terminated
Jun 26, 2020
Changes/Corrections After Pub Approval Entered
Jun 24, 2020
Assigned To Petition Staff
Jun 2, 2020
Teas Post Publication Amendment Received
Feb 11, 2020
Extension Of Time To Oppose Received
Jan 14, 2020
Official Gazette Publication Confirmation E-Mailed
Jan 14, 2020
Published For Opposition
Dec 25, 2019
Notification Of Notice Of Publication E-Mailed
Dec 12, 2019
Approved For Pub - Principal Register
Dec 11, 2019
Teas/Email Correspondence Entered
Dec 11, 2019
Correspondence Received In Law Office
Dec 11, 2019
Teas Response To Office Action Received
Jun 11, 2019
Notification Of Non-Final Action E-Mailed
Jun 11, 2019
Non-Final Action E-Mailed
Jun 11, 2019
Non-Final Action Written
Jun 4, 2019
Teas Change Of Correspondence Received
Jun 4, 2019
Teas/Email Correspondence Entered
Jun 4, 2019
Correspondence Received In Law Office
Jun 4, 2019
Teas Response To Office Action Received
Dec 6, 2018
Notification Of Non-Final Action E-Mailed
Dec 6, 2018
Non-Final Action E-Mailed
Dec 6, 2018
Non-Final Action Written
Dec 3, 2018
Assigned To Examiner
Aug 25, 2018
New Application Office Supplied Data Entered
Aug 20, 2018
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24